Drug Trial Radar · NCT05521438
Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
Last checked: Nov 19, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jun 23, 2022
Primary completion
Dec 30, 2025
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Quoin PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Aug 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study has been designed to determine the safety, tolerability and efficacy of QRX003 lotion 2%, 4% QAM or 4% BID in subjects with Netherton Syndrome (NS) in comparison to vehicle
Conditions
- Netherton Syndrome
Interventions
QRX003-2% LotionDrug
QRX003Topical Lotion containing 2% active drug (serine protease inhibitor)
QRX003-4% Lotion QAMDrug
QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
VehicleDrug
Vehicle Lotion
QRX003-4% Lotion BIDDrug
QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy Endpoints-1-point IGATime frame: Up to week 16
- Efficacy Endpoints-2-point IGATime frame: Up to week 16
- Efficacy Endpoints-NS SignTime frame: Up to week 16
- Efficacy Endpoints-BSATime frame: Up to week 16
- Efficacy Endpoints-WI-NRS scoreTime frame: Up to week 16
- Efficacy Endpoints-TSQMTime frame: Up to week 16
- Efficacy Endpoints-Rescue TherapyTime frame: Up to week 16
- Safety Endpoints-AEsTime frame: Up to week 16
- Safety Endpoints-LSRTime frame: Up to week 16
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Site #1
San Diego, California
Site #4
Indianapolis, Indiana
Site #5
Quincy, Massachusetts
Site #3
Charleston, South Carolina
Site #2
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.